Amylyx Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
AMLX$30.91+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows used in operating activities: | ||
| Net loss | $(41,284) | $(35,907) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 6,120 | 6,833 |
| Depreciation expense | 98 | 156 |
| Accretion of investment discounts, net | (609) | (1,703) |
| Charge for In-Process Research and Development ("IPR&D") milestones | 4,000 | — |
| Other non-cash items | 53 | — |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,433 | 879 |
| Operating lease right-of-use assets | 300 | 515 |
| Other assets | (2) | 13 |
| Accounts payable | 10 | 1,871 |
| Accrued expenses | (6,674) | (11,882) |
| Operating lease liabilities | (327) | (599) |
| Net cash used in operating activities | (36,882) | (39,824) |
| Cash flows provided by (used in) investing activities: | ||
| Purchases of property and equipment | — | (11) |
| Milestone payments related to IPR&D | (4,000) | — |
| Purchases of investments | (19,738) | (103,648) |
| Proceeds from maturities of marketable securities | 60,000 | 60,000 |
| Net cash provided by (used in) investing activities | 36,262 | (43,659) |
| Cash flows provided by financing activities: | ||
| Proceeds from financings, net of issuance costs | — | 65,577 |
| Proceeds from exercise of stock options and RSUs vesting | 7,159 | 970 |
| Withholding taxes paid on stock-based awards | (3,942) | (885) |
| Net cash provided by financing activities | 3,217 | 65,662 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | (111) | 197 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 2,486 | (17,624) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 227,636 | 78,837 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $230,122 | $61,213 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents: | ||
| Cash and cash equivalents | $229,136 | $59,764 |
| Restricted cash equivalents | 986 | 1,449 |
| Total cash, cash equivalents and restricted cash equivalents: | $230,122 | $61,213 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.